What exactly did H.C. Wainwright do on March 06, 2026?

On **March 06, 2026** H.C. Wainwright reiterated a **Buy** rating on Lineage Cell Therapeutics (LCTX). The firm did not raise or lower its price target in the note, and the publication is available on StreetInsider [source](https://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+By

How should investors interpret the LCTX analyst rating?

A maintained Buy means the analyst still expects upside under current assumptions. Investors should weigh clinical milestones, cash runway, and existing valuation before adjusting positions. The rating alone is not a trading signal without corroborating data.

Does the maintained Buy include a new price target for LCTX?

No. The H.C. Wainwright note on March 06, 2026 maintained the Buy without publishing a new price target. That leaves valuation upside tied to prior models and upcoming clinical readouts.

Analyst Ratings

H.C. Wainwright Maintains Buy on Lineage Cell Therapeutics (LCTX) Mar 2026

ByDanny Kontos March 9, 2026March 9, 2026

On March 06, 2026, H.C. Wainwright maintained a Buy on Lineage Cell Therapeutics, Inc. (LCTX), a move that anchors the LCTX analyst rating conversation this week. The note was published at 09:00 AM and followed company updates about OpRegen and AlloSCOPE progress. Investors should note the stock moved -3.71% (-$0.07) on the day of the note and the company shows a market cap of $418,044,480. This article summarizes the rating action, market reaction, and what the maintained Buy means for investors.